Before treatment, serum IL-6 levels were higher in MS patients than HC (mean 4.21 vs 1.41 pg/ml, p<0.001), and thereafter significantly changed during the follow up (ANOVA main effect of time: p<0.001; interaction term non-significant. The gene discussed is IL6; the disease is myeloid sarcoma.